Valentino Stella, Ph.D.
Val is a University Distinguished Professor at the University of Kansas with a BPharm from the Victorian College of Pharmacy, now Monash University, and his PhD from the University of Kansas in 1971. He is internationally recognized for his research involving novel ways of formulating and delivering problematic drug candidates, especially those used to treat cancer and AIDS.
Val is the inventor or co-inventor of the approved drugs fosphenytoin (Cerebyx®), Viread®, Lusedra®, the formulation covering Velcade®, and Captisol®, the solubilizer used in the injectable forms of Vfend®, Geodon®, Abilify®, Nexterone®, Kyprolis (carfilzomib)®, Noxafil-IV® and Cerenia.
Val's many honors include the American Pharmacists Association's Takeru Higuchi Research Prize, Distinguished Scientist award from the American Association of Pharmaceutical Scientists and is a Fellow of the AAAS and the National Academy of Inventors. Val has more than 300 publications, reviews and book chapters. He holds 45 issued U.S. Patents and many foreign patents.